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Although B cell depletion therapy (BCDT) is now a
well-accepted therapeutic option in autoimmune
rheumatic disease, a significant proportion of patients
remain resistant to therapy. .19pt?>A more challenging
clinical problem is the high rate of relapse after B cell
reconstitution, as well as the difficulty in predicting
the exact timing of that relapse. In this article, we
consider the immunological mechanisms that may
account for the heterogeneity of clinical response to
BCDT. Understanding how BCDT alters the balance
between different B cell subsets, some pathogenic
and some regulatory, may help us correctly target
BCDT to the right patients, and thereby improve
treatment responses in rheumatic disease.A further problem in assessing BCDT is that success-The identification of autoantibodies in the serum of
patients with rheumatic disease was one of the landmark
studies that placed B cells at the heart of research into
the pathogenesis of autoimmune disease. It is now clear
that B cells contribute to autoimmunity by a range of
mechanisms, both directly through the secretion of
inflammatory cytokines [1] and indirectly by antigen
presentation and co-stimulation to activate autoreactive
T cells. However, it was only at the beginning of the last
decade that attention finally turned to B cells as a poten-
tial target that may ameliorate autoimmune rheumatic
disease.
B-cell depletion therapy in rheumatic disease
Randomized controlled trials (RCTs) of the anti-CD20
antibody rituximab provided the first evidence that B-cell
depletion therapy (BCDT) reduces disease activity in
rheumatoid arthritis (RA). In systemic lupus erythema-
tosus (SLE), BCDT was found to be highly effective in* Correspondence: k.nistala@ucl.ac.uk
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2014routine clinical practice and open studies, and so it was
surprising that two RCTs of BCDT in SLE failed to meet
their primary end point [2,3]. This may relate, at least in
part, to issues of patient selection and trial design, such
as the use of concomitant high-dose corticosteroids
(reviewed in [4]). B-cell effector function may be im-
portant for predicting response to BCDT, as anti-CD20
therapy was successful in an animal model of multiple
sclerosis but only if B cells secreting IL-6 were contribut-
ing to pathology [5]. Whether this is true of autoimmune
rheumatic disease is still unclear. Certainly in clinical
practice, some RA patients resistant to BCDT still re-
spond to anti-IL-6 blockade, suggesting that alternative
sources of IL-6 may be important in disease persistence
(personal communication, David Isenberg, University
College London).
ful depletion is defined by circulating total B-cell counts
and this disregards the diversity of B-cell phenotype,
function, and compartmentalization. A pooled analysis
of more than 800 patients from different RCTs indicated
that plasmablast markers are useful in identifying a
subgroup of non-responders in RA [6]. Also, long-lived
plasma cells that express low levels of CD20 and reside
within the bone marrow and spleen may further contribute
to persist disease as seen in the case of patients with
immune thrombocytopenia treated with rituximab [7]. In
SLE, increased serum levels of the B cell-activating factor
following repeated rituximab therapy were associated with
elevated anti-double-stranded-DNA antibodies and disease
flare [8]. Taken together, these studies suggest that con-
tinued activity of plasmablasts/plasma cells may be one
explanation for the persistence of disease following BCDT.
As well as predicting resistance to initial BCDT, a fur-
ther clinical challenge is to prevent relapse of disease in
those patients who have undergone remission. In some
patients, relapse closely follows B-cell repopulation,
whereas in others relapse can be delayed for years [9,10].
These data suggest that the functional characteristics ofntral Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Note: This article is part of the collection ‘Why is there persistent
disease despite aggressive therapy of rheumatoid arthritis?’, edited
by Pierre Miossec. Other articles in this series can be found at
http://arthritis-research.com/series/residual.
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than the simple fact of reconstitution.
Understanding B-cell heterogeneity – the role of
regulatory B cells
Over the last decade, our group, and others, have identified
a novel subset of B cells with an immunoregulatory role
rather than one of pathogen clearance. These regulatory B
(Breg) cells function in an IL-10-dependent manner [11] to
suppress inflammatory T-cell responses and induce regula-
tory T cells, leading to the suppression of arthritis and lupus
in mouse models [11,12]. We have recently discovered,
within the circulating immature B-cell compartment in
humans, similar populations of cells that are the equivalent
of murine Breg cells. These human Breg cells restrain T-cell
responses in vitro and are numerically or functionally defi-
cient in rituximab-naïve patients with RA and SLE [13,14].
Although Breg cells express CD20 and are likely to be
depleted by BCD, the effects of a reduced immune regula-
tory pool may be masked by the simultaneous reduction in
pathogenic B cells. However, this temporary status quo is
unstable and may be easily disturbed depending on which
B-cell population is first to repopulate after BCDT. Given
that immature cells are often the first B cells to return in
circulation [15], we predict that these cells, rather than con-
tributing to disease relapse, may in fact be regulatory and
thus play an important role in maintaining immune toler-
ance after BCDT. Our recent data exploring the interaction
between Breg cells and invariant natural killer T (iNKT)
cells, a rare subset of innate-like T cells with homeostatic
function, support this hypothesis. In health, immature B
cells promote the expansion of anti-inflammatory iNKT
cells [16], whereas B cells from patients with active SLE are
defective and fail to maintain iNKT cells, leading to signifi-
cantly reduced iNKT cell numbers in circulation. Following
BCD, patients who repopulated with immature B cells
normalized iNKT cell numbers and maintained a clinical
response to BCDT. These data suggest that repopulation of
B cells with a regulatory phenotype may be important in
maintaining clinical remission. In contrast, the repopulation
with circulating memory B cells or plasmablasts has been
associated with earlier relapse of disease in SLE [17].
Therefore, it is likely that the initial response to BCDT, as
well as the risk of disease relapse afterwards, depends on
the specific mechanisms of B-cell pathology and the bal-
ance between effector and Breg cell subsets in the individual
patient. To identify biomarkers that can accurately predict
response to BCDT, we need a better understanding of B-
cell heterogeneity and surface markers that can precisely
distinguish B cells with effector or regulatory function.
These results would open up the possibility of screening pa-
tients prior to BCD to assess effector/regulatory balance
and see whether this better predicts treatment response.
Importantly, this work offers a chance to move toward amore personalized form of BCDT, one that will hopefully
reduce the risks of treatment resistance and relapse in auto-
immune rheumatic disease.Abbreviations
BCD: B-cell depletion; BCDT: B-cell depletion therapy; Breg: regulatory B;
IL: interleukin; iNKT: invariant natural killer T; RA: rheumatoid arthritis;
RCT: randomized controlled trial; SLE: systemic lupus erythematosus.
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